CMS5
MCID: MYS051
MIFTS: 45

Myasthenic Syndrome, Congenital, 5 (CMS5)

Categories: Eye diseases, Fetal diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Myasthenic Syndrome, Congenital, 5

MalaCards integrated aliases for Myasthenic Syndrome, Congenital, 5:

Name: Myasthenic Syndrome, Congenital, 5 57 75
Endplate Acetylcholinesterase Deficiency 57 75 29 13 55 6 73
Engel Congenital Myasthenic Syndrome 57 12 75
Cms5 57 12 75
Ead 57 12 75
Myasthenic Syndrome, Congenital, Engel Type 57 75
Congenital Myasthenic Syndrome Type Ic 12 75
Congenital Myasthenic Syndrome 5 12 15
Cms Ic 12 75
Congenital Myasthenic Syndrome Type Ic, Formerly; Cms1c, Formerly 57
Congenital Myasthenic Syndrome Type Ic, Formerly 57
Endplate Acetylcholinesterase Deficiency; Ead 57
Myasthenic Syndrome, Congenital, Type 5 ) 40
Congenital Myasthenic Syndrome Engel Type 12
End Plate Acetylcholinesterase Deficiency 12
End-Plate Acetylcholinesterase Deficiency 75
Synaptic Congenital Myasthenic Syndromes 59
Congenital Myasthenic Syndrome Type 1c 75
Cms Ic, Formerly 57
Cms1c, Formerly 57
Cms1c 75
Cmse 75

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive

Miscellaneous:
onset usually in infancy
later childhood onset has been reported
phenotypic variation in severity and symptoms
no response or worsening with acetylcholinesterase inhibitors
symptoms progress with worsening myopathy


HPO:

32
myasthenic syndrome, congenital, 5:
Onset and clinical course infantile onset
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Myasthenic Syndrome, Congenital, 5

OMIM : 57 Congenital myasthenic syndromes (CMS) are a group of inherited disorders affecting the neuromuscular junction. Patients present clinically with onset of variable muscle weakness between infancy and adulthood. These disorders have been classified according to the location of the defect: presynaptic, synaptic, and postsynaptic. Endplate acetylcholinesterase deficiency is an autosomal recessive congenital myasthenic syndrome characterized by a defect within the synapse at the neuromuscular junction (NMJ). Mutations in COLQ result in a deficiency of acetylcholinesterase (AChE), which causes prolonged synaptic currents and action potentials due to extended residence of acetylcholine in the synaptic space. Treatment with ephedrine may be beneficial; AChE inhibitors and amifampridine should be avoided (summary by Engel et al., 2015). For a discussion of genetic heterogeneity of CMS, see CMS1A (601462). (603034)

MalaCards based summary : Myasthenic Syndrome, Congenital, 5, also known as endplate acetylcholinesterase deficiency, is related to congenital myasthenic syndrome and schwartz-jampel syndrome, type 1, and has symptoms including ophthalmoparesis An important gene associated with Myasthenic Syndrome, Congenital, 5 is COLQ (Collagen Like Tail Subunit Of Asymmetric Acetylcholinesterase), and among its related pathways/superpathways is PIWI-interacting RNA (piRNA) biogenesis. The drugs Pseudoephedrine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, skeletal muscle and heart, and related phenotypes are high palate and ptosis

Disease Ontology : 12 A congenital myasthenic syndrome characterized by autosomal recessive inheritance of a defect within the synapse at the neuromuscular junction resulting in prolonged synaptic currents and action potentials that has material basis in homozygous or compound heterozygous mutation in the COLQ gene on chromosome 3p25.

UniProtKB/Swiss-Prot : 75 Myasthenic syndrome, congenital, 5: A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre- synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS5 inheritance is autosomal recessive.

Related Diseases for Myasthenic Syndrome, Congenital, 5

Graphical network of the top 20 diseases related to Myasthenic Syndrome, Congenital, 5:



Diseases related to Myasthenic Syndrome, Congenital, 5

Symptoms & Phenotypes for Myasthenic Syndrome, Congenital, 5

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Eyes:
ptosis
ophthalmoparesis
slow, delayed pupillary light reflex

Abdomen Gastrointestinal:
dysphagia
poor feeding due to muscle weakness

Respiratory:
respiratory insufficiency due to muscle weakness

Muscle Soft Tissue:
muscle biopsy shows type 2 fiber atrophy
underdeveloped muscles
muscle biopsy shows endplate myopathy (see details under neurologic heading)

Neurologic Peripheral Nervous System:
dysarthria
easy fatigability
hypotonia
limb weakness
prolonged miniature endplate potentials (mepp)
more
Skeletal Spine:
scoliosis
lordosis

Voice:
weak cry

Immunology:
absence of acetylcholine receptor (achr) autoantibodies


Clinical features from OMIM:

603034

Human phenotypes related to Myasthenic Syndrome, Congenital, 5:

59 32 (show top 50) (show all 65)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 high palate 59 32 occasional (7.5%) Occasional (29-5%) HP:0000218
2 ptosis 59 32 Frequent (79-30%) HP:0000508
3 intellectual disability 59 32 occasional (7.5%) Occasional (29-5%) HP:0001249
4 muscular hypotonia 59 32 frequent (33%) Frequent (79-30%) HP:0001252
5 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
6 respiratory insufficiency 59 32 Frequent (79-30%) HP:0002093
7 scoliosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002650
8 sleep apnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0010535
9 facial palsy 59 32 frequent (33%) Frequent (79-30%) HP:0010628
10 mandibular prognathia 59 32 very rare (1%) Very rare (<4-1%) HP:0000303
11 global developmental delay 59 32 frequent (33%) Frequent (79-30%) HP:0001263
12 abnormal facial shape 59 32 very rare (1%) Very rare (<4-1%) HP:0001999
13 myopathy 59 32 frequent (33%) Frequent (79-30%) HP:0003198
14 generalized muscle weakness 59 32 hallmark (90%) Very frequent (99-80%) HP:0003324
15 skeletal muscle atrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0003202
16 pulmonary arterial hypertension 59 32 very rare (1%) Very rare (<4-1%) HP:0002092
17 respiratory distress 59 32 frequent (33%) Frequent (79-30%) HP:0002098
18 waddling gait 59 32 frequent (33%) Frequent (79-30%) HP:0002515
19 scapular winging 59 32 frequent (33%) Frequent (79-30%) HP:0003691
20 ophthalmoparesis 59 32 frequent (33%) Frequent (79-30%) HP:0000597
21 talipes equinovarus 59 32 very rare (1%) Very rare (<4-1%) HP:0001762
22 easy fatigability 59 32 occasional (7.5%) Occasional (29-5%) HP:0003388
23 type 1 muscle fiber predominance 59 32 occasional (7.5%) Occasional (29-5%) HP:0003803
24 areflexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001284
25 hyporeflexia 59 32 frequent (33%) Frequent (79-30%) HP:0001265
26 proximal muscle weakness 59 32 hallmark (90%) Very frequent (99-80%) HP:0003701
27 weak cry 59 32 frequent (33%) Frequent (79-30%) HP:0001612
28 recurrent lower respiratory tract infections 59 32 occasional (7.5%) Occasional (29-5%) HP:0002783
29 hypoventilation 59 32 occasional (7.5%) Occasional (29-5%) HP:0002791
30 axial muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0003327
31 neck muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0000467
32 frequent falls 59 32 very rare (1%) Very rare (<4-1%) HP:0002359
33 distal muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0002460
34 poor suck 59 32 frequent (33%) Frequent (79-30%) HP:0002033
35 neonatal respiratory distress 59 32 occasional (7.5%) Occasional (29-5%) HP:0002643
36 exertional dyspnea 59 32 very rare (1%) Very rare (<4-1%) HP:0002875
37 poor head control 59 32 frequent (33%) Frequent (79-30%) HP:0002421
38 hand muscle weakness 59 32 very rare (1%) Very rare (<4-1%) HP:0030237
39 abnormality of the knee 59 32 occasional (7.5%) Occasional (29-5%) HP:0002815
40 abnormal enzyme/coenzyme activity 59 32 frequent (33%) Frequent (79-30%) HP:0012379
41 bilateral ptosis 59 32 frequent (33%) Frequent (79-30%) HP:0001488
42 type 2 muscle fiber atrophy 59 32 very rare (1%) Very rare (<4-1%) HP:0003554
43 right ventricular hypertrophy 59 32 very rare (1%) Very rare (<4-1%) HP:0001667
44 limited wrist extension 59 32 very rare (1%) Very rare (<4-1%) HP:0006251
45 triangular mouth 59 32 very rare (1%) Very rare (<4-1%) HP:0000207
46 decreased size of nerve terminals 59 32 frequent (33%) Frequent (79-30%) HP:0003443
47 prolonged miniature endplate currents 59 32 frequent (33%) Frequent (79-30%) HP:0003436
48 unfavorable response of muscle weakness to acetylcholine esterase inhibitors 59 32 frequent (33%) Frequent (79-30%) HP:0030203
49 limited extraocular movements 59 32 occasional (7.5%) Occasional (29-5%) HP:0007941
50 slow pupillary light response 59 32 occasional (7.5%) Occasional (29-5%) HP:0030211

UMLS symptoms related to Myasthenic Syndrome, Congenital, 5:


ophthalmoparesis

GenomeRNAi Phenotypes related to Myasthenic Syndrome, Congenital, 5 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased caspase activity GR00400-S-1 9.17 HRASLS5 POLR2D POLR2G
2 Increased caspase activity GR00400-S-2 9.17 HRASLS5 PGAM1 POLR2D POLR2G

Drugs & Therapeutics for Myasthenic Syndrome, Congenital, 5

Drugs for Myasthenic Syndrome, Congenital, 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pseudoephedrine Approved Phase 1, Phase 2 90-82-4 7028
2
Ephedrine Approved Phase 1, Phase 2 299-42-3 9294
3 Vasoconstrictor Agents Phase 1, Phase 2
4 Adrenergic Agents Phase 1, Phase 2
5 Central Nervous System Stimulants Phase 1, Phase 2
6 Sympathomimetics Phase 1, Phase 2
7 Respiratory System Agents Phase 1, Phase 2
8 Anti-Asthmatic Agents Phase 1, Phase 2
9 Neurotransmitter Agents Phase 1, Phase 2
10 Peripheral Nervous System Agents Phase 1, Phase 2
11 Bronchodilator Agents Phase 1, Phase 2
12 Autonomic Agents Phase 1, Phase 2
13 Nasal Decongestants Phase 1, Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Ephedrine for the Treatment of Congenital Myasthenia Unknown status NCT00541216 Phase 1, Phase 2 Ephedrine

Search NIH Clinical Center for Myasthenic Syndrome, Congenital, 5

Genetic Tests for Myasthenic Syndrome, Congenital, 5

Genetic tests related to Myasthenic Syndrome, Congenital, 5:

# Genetic test Affiliating Genes
1 Endplate Acetylcholinesterase Deficiency 29 COLQ

Anatomical Context for Myasthenic Syndrome, Congenital, 5

MalaCards organs/tissues related to Myasthenic Syndrome, Congenital, 5:

41
Eye, Skeletal Muscle, Heart

Publications for Myasthenic Syndrome, Congenital, 5

Articles related to Myasthenic Syndrome, Congenital, 5:

# Title Authors Year
1
Mechanism hypotheses for the electrophysiological manifestations of two cases of endplate acetylcholinesterase deficiency related congenital myasthenic syndrome. ( 29150079 )
2018
2
Mutations in the C-terminal domain of ColQ in endplate acetylcholinesterase deficiency compromise ColQ-MuSK interaction. ( 23553736 )
2013
3
Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. ( 21952943 )
2011
4
Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz-Jampel syndrome neuromyotonia. ( 18647752 )
2008
5
Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. ( 16009904 )
2005
6
Two novel mutations in the COLQ gene cause endplate acetylcholinesterase deficiency. ( 12609505 )
2003
7
Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. ( 9689136 )
1998
8
Treatment of congenital endplate acetylcholinesterase deficiency by neuromuscular blockade. ( 8807428 )
1996
9
Congenital endplate acetylcholinesterase deficiency. ( 8390325 )
1993

Variations for Myasthenic Syndrome, Congenital, 5

UniProtKB/Swiss-Prot genetic disease variations for Myasthenic Syndrome, Congenital, 5:

75
# Symbol AA change Variation ID SNP ID
1 COLQ p.Pro59Gln VAR_010133
2 COLQ p.Asp342Glu VAR_010134 rs758554049
3 COLQ p.Arg410Gln VAR_010135 rs102536162
4 COLQ p.Tyr430Ser VAR_010136 rs121908923
5 COLQ p.Cys444Tyr VAR_010137
6 COLQ p.Ile337Thr VAR_071710 rs105752115

ClinVar genetic disease variations for Myasthenic Syndrome, Congenital, 5:

6 (show top 50) (show all 112)
# Gene Variation Type Significance SNP ID Assembly Location
1 COLQ COLQ, 215-BP DEL, NT107 deletion Pathogenic
2 COLQ NM_005677.3(COLQ): c.640G> T (p.Glu214Ter) single nucleotide variant Pathogenic rs104893733 GRCh37 Chromosome 3, 15512120: 15512120
3 COLQ NM_005677.3(COLQ): c.640G> T (p.Glu214Ter) single nucleotide variant Pathogenic rs104893733 GRCh38 Chromosome 3, 15470613: 15470613
4 COLQ NM_005677.3(COLQ): c.506C> G (p.Ser169Ter) single nucleotide variant Pathogenic rs104893734 GRCh37 Chromosome 3, 15516954: 15516954
5 COLQ NM_005677.3(COLQ): c.506C> G (p.Ser169Ter) single nucleotide variant Pathogenic rs104893734 GRCh38 Chromosome 3, 15475447: 15475447
6 COLQ NM_005677.3(COLQ): c.844A> T (p.Arg282Ter) single nucleotide variant Pathogenic rs121908922 GRCh37 Chromosome 3, 15499803: 15499803
7 COLQ NM_005677.3(COLQ): c.844A> T (p.Arg282Ter) single nucleotide variant Pathogenic rs121908922 GRCh38 Chromosome 3, 15458296: 15458296
8 COLQ NM_005677.3(COLQ): c.1082delC (p.Pro361Leufs) deletion Pathogenic rs769982050 GRCh37 Chromosome 3, 15497519: 15497519
9 COLQ NM_005677.3(COLQ): c.1082delC (p.Pro361Leufs) deletion Pathogenic rs769982050 GRCh38 Chromosome 3, 15456012: 15456012
10 COLQ NM_005677.3(COLQ): c.788dupC (p.Pro265Alafs) duplication Pathogenic rs759911990 GRCh37 Chromosome 3, 15507874: 15507874
11 COLQ NM_005677.3(COLQ): c.788dupC (p.Pro265Alafs) duplication Pathogenic rs759911990 GRCh38 Chromosome 3, 15466367: 15466367
12 COLQ NM_005677.3(COLQ): c.1289A> C (p.Tyr430Ser) single nucleotide variant Pathogenic rs121908923 GRCh37 Chromosome 3, 15495345: 15495345
13 COLQ NM_005677.3(COLQ): c.1289A> C (p.Tyr430Ser) single nucleotide variant Pathogenic rs121908923 GRCh38 Chromosome 3, 15453838: 15453838
14 COLQ NM_005677.3(COLQ): c.943C> T (p.Arg315Ter) single nucleotide variant Pathogenic rs121908924 GRCh37 Chromosome 3, 15499704: 15499704
15 COLQ NM_005677.3(COLQ): c.943C> T (p.Arg315Ter) single nucleotide variant Pathogenic rs121908924 GRCh38 Chromosome 3, 15458197: 15458197
16 COLQ COLQ, IVS16DS, A-G, +3 single nucleotide variant Pathogenic
17 COLQ NM_005677.3(COLQ): c.718G> T (p.Gly240Ter) single nucleotide variant Pathogenic rs104893735 GRCh37 Chromosome 3, 15507944: 15507944
18 COLQ NM_005677.3(COLQ): c.718G> T (p.Gly240Ter) single nucleotide variant Pathogenic rs104893735 GRCh38 Chromosome 3, 15466437: 15466437
19 COLQ NM_005677.3(COLQ): c.1248C> T (p.Asp416=) single nucleotide variant Benign/Likely benign rs55866379 GRCh37 Chromosome 3, 15495386: 15495386
20 COLQ NM_005677.3(COLQ): c.1248C> T (p.Asp416=) single nucleotide variant Benign/Likely benign rs55866379 GRCh38 Chromosome 3, 15453879: 15453879
21 COLQ NM_005677.3(COLQ): c.366+7A> G single nucleotide variant Benign/Likely benign rs750387 GRCh37 Chromosome 3, 15520838: 15520838
22 COLQ NM_005677.3(COLQ): c.366+7A> G single nucleotide variant Benign/Likely benign rs750387 GRCh38 Chromosome 3, 15479331: 15479331
23 COLQ NM_005677.3(COLQ): c.934A> G (p.Ser312Gly) single nucleotide variant Benign/Likely benign rs6782980 GRCh37 Chromosome 3, 15499713: 15499713
24 COLQ NM_005677.3(COLQ): c.934A> G (p.Ser312Gly) single nucleotide variant Benign/Likely benign rs6782980 GRCh38 Chromosome 3, 15458206: 15458206
25 COLQ NM_005677.3(COLQ): c.291G> A (p.Ser97=) single nucleotide variant Benign/Likely benign rs115201284 GRCh37 Chromosome 3, 15529743: 15529743
26 COLQ NM_005677.3(COLQ): c.291G> A (p.Ser97=) single nucleotide variant Benign/Likely benign rs115201284 GRCh38 Chromosome 3, 15488236: 15488236
27 COLQ NM_005677.3(COLQ): c.391A> G (p.Lys131Glu) single nucleotide variant Uncertain significance rs142980906 GRCh37 Chromosome 3, 15520486: 15520486
28 COLQ NM_005677.3(COLQ): c.391A> G (p.Lys131Glu) single nucleotide variant Uncertain significance rs142980906 GRCh38 Chromosome 3, 15478979: 15478979
29 COLQ NM_005677.3(COLQ): c.1338C> A (p.Ile446=) single nucleotide variant Benign/Likely benign rs73818504 GRCh38 Chromosome 3, 15451674: 15451674
30 COLQ NM_005677.3(COLQ): c.1338C> A (p.Ile446=) single nucleotide variant Benign/Likely benign rs73818504 GRCh37 Chromosome 3, 15493181: 15493181
31 COLQ NM_005677.3(COLQ): c.1108G> A (p.Asp370Asn) single nucleotide variant Benign/Likely benign rs116373583 GRCh38 Chromosome 3, 15455986: 15455986
32 COLQ NM_005677.3(COLQ): c.1108G> A (p.Asp370Asn) single nucleotide variant Benign/Likely benign rs116373583 GRCh37 Chromosome 3, 15497493: 15497493
33 COLQ NM_005677.3(COLQ): c.72G> A (p.Pro24=) single nucleotide variant Likely benign rs111339593 GRCh37 Chromosome 3, 15563061: 15563061
34 COLQ NM_005677.3(COLQ): c.72G> A (p.Pro24=) single nucleotide variant Likely benign rs111339593 GRCh38 Chromosome 3, 15521554: 15521554
35 COLQ NM_005677.3(COLQ): c.679C> T (p.Arg227Ter) single nucleotide variant Pathogenic rs770045897 GRCh37 Chromosome 3, 15512081: 15512081
36 COLQ NM_005677.3(COLQ): c.679C> T (p.Arg227Ter) single nucleotide variant Pathogenic rs770045897 GRCh38 Chromosome 3, 15470574: 15470574
37 COLQ NM_005677.3(COLQ): c.529-2A> G single nucleotide variant Pathogenic rs755236236 GRCh37 Chromosome 3, 15516460: 15516460
38 COLQ NM_005677.3(COLQ): c.529-2A> G single nucleotide variant Pathogenic rs755236236 GRCh38 Chromosome 3, 15474953: 15474953
39 COLQ NM_005677.3(COLQ): c.23C> G (p.Thr8Ser) single nucleotide variant Benign/Likely benign rs189427175 GRCh37 Chromosome 3, 15563110: 15563110
40 COLQ NM_005677.3(COLQ): c.23C> G (p.Thr8Ser) single nucleotide variant Benign/Likely benign rs189427175 GRCh38 Chromosome 3, 15521603: 15521603
41 COLQ NM_005677.3(COLQ): c.106+6T> C single nucleotide variant Uncertain significance rs201376373 GRCh37 Chromosome 3, 15563021: 15563021
42 COLQ NM_005677.3(COLQ): c.106+6T> C single nucleotide variant Uncertain significance rs201376373 GRCh38 Chromosome 3, 15521514: 15521514
43 COLQ NM_005677.3(COLQ): c.1081C> T (p.Pro361Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs116828761 GRCh37 Chromosome 3, 15497520: 15497520
44 COLQ NM_005677.3(COLQ): c.1081C> T (p.Pro361Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs116828761 GRCh38 Chromosome 3, 15456013: 15456013
45 COLQ NM_005677.3(COLQ): c.912C> T (p.Tyr304=) single nucleotide variant Conflicting interpretations of pathogenicity rs886058099 GRCh38 Chromosome 3, 15458228: 15458228
46 COLQ NM_005677.3(COLQ): c.912C> T (p.Tyr304=) single nucleotide variant Conflicting interpretations of pathogenicity rs886058099 GRCh37 Chromosome 3, 15499735: 15499735
47 COLQ NM_005677.3(COLQ): c.561C> T (p.Ser187=) single nucleotide variant Conflicting interpretations of pathogenicity rs149370622 GRCh38 Chromosome 3, 15474267: 15474267
48 COLQ NM_005677.3(COLQ): c.561C> T (p.Ser187=) single nucleotide variant Conflicting interpretations of pathogenicity rs149370622 GRCh37 Chromosome 3, 15515774: 15515774
49 COLQ NM_005677.3(COLQ): c.788C> T (p.Pro263Leu) single nucleotide variant Uncertain significance rs146619514 GRCh38 Chromosome 3, 15466367: 15466367
50 COLQ NM_005677.3(COLQ): c.788C> T (p.Pro263Leu) single nucleotide variant Uncertain significance rs146619514 GRCh37 Chromosome 3, 15507874: 15507874

Expression for Myasthenic Syndrome, Congenital, 5

Search GEO for disease gene expression data for Myasthenic Syndrome, Congenital, 5.

Pathways for Myasthenic Syndrome, Congenital, 5

Pathways related to Myasthenic Syndrome, Congenital, 5 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.09 POLR2D POLR2G

GO Terms for Myasthenic Syndrome, Congenital, 5

Cellular components related to Myasthenic Syndrome, Congenital, 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basement membrane GO:0005604 9.33 ACHE COLQ LAMB2
2 RNA polymerase II, core complex GO:0005665 9.26 POLR2D POLR2G
3 neuromuscular junction GO:0031594 9.13 ACHE COLQ LAMB2
4 synaptic cleft GO:0043083 8.8 ACHE COLQ LAMB2

Biological processes related to Myasthenic Syndrome, Congenital, 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of translational initiation GO:0045948 9.32 POLR2D POLR2G
2 ventricular cardiac muscle cell action potential GO:0086005 9.26 KCNH2 RYR2
3 neurotransmitter catabolic process GO:0042135 9.16 ACHE COLQ
4 phosphorelay signal transduction system GO:0000160 8.96 KCNH1 KCNH2
5 acetylcholine catabolic process in synaptic cleft GO:0001507 8.62 ACHE COLQ

Molecular functions related to Myasthenic Syndrome, Congenital, 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.33 KCNH1 KCNH2 RYR2
2 translation initiation factor binding GO:0031369 8.96 POLR2D POLR2G
3 phosphorelay sensor kinase activity GO:0000155 8.62 KCNH1 KCNH2

Sources for Myasthenic Syndrome, Congenital, 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....